A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark | E+ | Getty Images Felix is five years old, loves food, and refuses to lose weight. His owner, Amy in Dallas, has tried cutting back on meals, but with two cats in the house, “he just gobbles…
Read More “Fat cat? Weight-loss drugs may be coming for your overweight pet” »
Moderna’s expanding pipeline beyond infectious diseases is giving investors a new reason to own the stock after years of uncertainty following the Covid-19 pandemic, CNBC’s Jim Cramer said Wednesday. “For the first time in a long time, the company seems like it has something to get excited about,” the “Mad Money” host said, before advising…
Read More “Jim Cramer says this former Covid market darling is finally investable again” »
Boxes of medication are seen on the shelves of the Keencare pharmacy, a member of the Green Light Group, on September 19, 2024 in London, England. Leon Neal | Getty Images News | Getty Images Once the go-to location for global drugmakers, Europe is now being squeezed by President Donald Trump’s aggressive trade and drug-pricing…
Read More “Trump policies, China’s biotech boom are ending Europe’s pharma powerhouse era” »
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney condition succeeded in a Phase 3 trial, a crucial step in the company’s path to diversify beyond its main drugs for cystic fibrosis. The Boston-based drugmaker on…
Read More “Vertex passes key test in quest to treat kidney diseases” »
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors,…
Read More “These innovative biotech stocks have a good chance of breaking out in 2025” »
